证券代码：600535 证券简称：天士力 编号：临 2025-006 号 天士力医药集团股份有限公司 关于 2025 年度预计发生的日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次日常关联交易尚需提交股东大会审议。 本次日常关联交易是公司生产经营需要发生的日常经营性业务往来，以市场价 格为基础协商定价，公平合理，对公司持续经营能力、盈利能力及资产独立性等不会产 生不利影响，不会对关联方形成较大的依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司 2025 年第一次独立董事专门会议审议通过了《关于 2025 年度预计发生的日 常关联交易的议案》，认为公司 2025 年日常关联交易预测以 2024 年日常关联交易数据 及 2025 年经营计划为基础，符合公司的实际情况，交易定价公允，具有合理性，并严 格按照相关规定履行批准程序，不会对公司独立性造成不利影响，公司不会因此而对关 联方形成依赖，不存在损害公司及全体股东特别是中小股东利益的情形，一致同意将该 项议案提交 ...

2024 年度会计师事务所履职情况评估报告 天士力医药集团股份有限公司（以下简称"公司"）聘请天健会计师事务所（特 殊普通合伙）（以下简称"天健事务所"）为公司 2024 年度财务报告审计机构及 内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选 聘会计师事务所管理办法》，公司对天健事务所 2024 年审计过程中的履职情况进 行评估。经评估，公司认为天健事务所资质等方面合规有效，履职保持独立性，勤 勉尽责，公允表达意见，具体情况如下： 天士力医药集团股份有限公司 一、会计师事务所情况 （一）会计师事务所基本情况 1、人力及其他资源配备 1 天健事务所为公司项目配备了专属的审计工作团队，核心团队成员均具备多年 上市公司、制造行业审计经验，并拥有中国注册会计师等专业资质。项目负责人由 资深审计服务合伙人担任。专业配置合理，人数、执业水平和经验等满足项目要求。 2、审计工作方案 按照《审计业务约定书》、《中国注册会计师审计准则》和其他执业规范及公司 2024 年年度报告的工作安排，天健事务所对公司 2024 年度财务报告及 2024 年 12 月 31 日的财务报告内部控制的有效性进行了审计， ...

地址： 天津市北辰区普济河东道2号天士力大健康城｜（Add ） Tasly Great Health Garden, No.2, Pujihe East Road, Beichen District, Tianjin 电话（Tel）: 022-2673-6688 | 传真（Fax）: 022-26736698 | 邮编（RC.）: 300410 | 网址（Web）: www.taslypharma.com 2024 社会责任报告 生 命 因 爱 而 动 Environmental,Social and Governance Report ( 天士力 TASLY 生 命 因 爱 而 动 编制依据 TASLY PHARMACEUTICAL GROUP CO., LTD. 2024年度社会责任报告 Environmental,Social and Governance Report 天士力医药集团股份有限公司 TASLY PHARMACEUTICAL GROUP CO., LT9. 关于本报告 报告简介 《天士力医药集团股份有限公司 2024年度社会责任报告》(以下统称"本报告") 是天士力医药集团股份有限公司发布 ...

证券代码：600535 证券简称：天士力 编号：临 2025-011 号 天士力医药集团股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 17 日 至 2025 年 3 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股东大会召开日期：2025年3月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 (一) 股东大会类型和届次 2024 年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网 ...

天士力医药集团股份有限公司 证券代码：600535 证券简称：天士力 编号：临 2025-004 号 第九届监事会第 4 次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届监事会第 4 次会议 通知和会议材料于 2025 年 2 月 11 日向全体监事及公司高级管理人员以直接送达、 邮寄等方式发出，会议于 2025 年 2 月 21 日 12:00 在公司天津本部会议室召开。会 议采取现场方式召开，会议应到监事 5 人，实到 5 人，监事陆振先生以视频方式出 席会议，公司高级管理人员全部列席本次会议。会议的召开符合《公司法》和《公 司章程》的有关规定。会议由监事会主席鞠爱春先生主持，审议通过了如下事项： 1、2024 年度总经理工作报告 表决情况为：有效表决票 5 票，其中：同意 5 票，反对 0 票，弃权 0 票。 2、2024 年度监事会工作报告 表决情况为：有效表决票 5 票，其中：同意 5 票，反对 0 票，弃权 0 票。 3、2024 年度财务决 ...

证券代码：600535 证券简称：天士力 编号：临 2025-003 号 天士力医药集团股份有限公司 第九届董事会第 5 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"或"本公司"）第九届董事 会第 5 次会议通知和会议材料于 2025 年 2 月 11 日向全体董事、监事及公司高级 管理人员以直接送达、邮寄等方式发出，会议于 2025 年 2 月 21 日上午 9:30 在公 司天津本部会议室以现场方式召开。 会议应到董事 9 人，实到 9 人，现场出席的董事有闫凯境董事长、蒋晓萌副 董事长、蔡金勇董事兼总经理、李克新董事、周水平董事、张斌独立董事、王爱 俭独立董事、韩秀桃独立董事，孙鹤副董事长视频参会。公司监事、高级管理人 员等相关人员列席会议。会议符合《公司法》和《公司章程》的有关规定，会议 合法、有效。会议由公司董事长闫凯境先生主持，经与会人员逐项审议，通过了 以下议案： 1、2024 年度总经理工作报告 表决情况为：有效表决票 9 票，其中：同意 9 ...

Financial Performance - The total distributable profit as of December 31, 2024, is RMB 6,920,089,279.23[3] - The proposed cash dividend is RMB 2 per 10 shares, totaling RMB 298,790,001.00 (including tax) for the current year[3] - The total cash dividends distributed for the year, including interim dividends, amount to RMB 791,793,502.65 (including tax), representing 82.86% of the net profit attributable to shareholders[3] - The company's operating revenue for 2024 was approximately ¥8.50 billion, a decrease of 2.03% compared to ¥8.67 billion in 2023[18] - Net profit attributable to shareholders was approximately ¥955.59 million, down 10.78% from ¥1.07 billion in 2023[18] - The basic earnings per share decreased to ¥0.64, reflecting an 11.11% decline from ¥0.72 in the previous year[19] - The net cash flow from operating activities was approximately ¥2.01 billion, down 21.78% from ¥2.58 billion in 2023[18] - The total assets decreased by 10.40% to approximately ¥14.98 billion from ¥16.71 billion in 2023[18] - The weighted average return on net assets was 7.68%, down 1.07 percentage points from 8.75% in 2023[19] Revenue and Cost Analysis - The company's pharmaceutical industrial revenue grew by 2.06% to ¥7.57 billion, while pharmaceutical commercial revenue fell by 26.39%[19] - The company's operating costs decreased by 3.05% year-on-year, with pharmaceutical industrial costs increasing by 9.13% and pharmaceutical commercial costs decreasing by 30.99%[77] - The gross margin for the pharmaceutical industrial segment was 71.08%, reflecting a decrease of 1.87% year-on-year[78] - Revenue from the cold and fever product line dropped by 39.48%, primarily due to decreased sales of specific products[79] - The production volume of the compound Danshen dripping pill was approximately 157.89 million boxes, with a sales volume of 153.95 million boxes, reflecting a year-on-year increase of 4.59% in production[80] Research and Development - The company has a pipeline of 98 products under development, including 33 Class 1 innovative drugs, with 27 in clinical trials and 22 in Phase II or III trials[29] - The company is focusing on high-quality development in the pharmaceutical industry, enhancing R&D capabilities and upgrading market strategies[28] - The company has successfully registered several drugs, including 10mg Rivaroxaban tablets and 30mg, 60mg Dapoxetine hydrochloride tablets, and submitted production applications for multiple other products[29] - The company is actively pursuing FDA clinical trial approvals for its innovative therapies, including stem cell injections for acute ischemic stroke[29] - The company has developed a new drug JS1-1-01 for depression, which has completed all subject enrollment in the domestic Phase II clinical trial[37] - The company has integrated a medical service system, transitioning from a product sales model to a service-oriented approach, enhancing the value marketing throughout the entire value chain[48] Market Strategy and Digital Transformation - The company is enhancing its marketing strategy by integrating academic promotion and digital marketing to improve product coverage and brand value[30] - The company has established a digital brand communication loop to enhance the dissemination of academic information and product value[31] - The company has launched a digital healthcare service model, enhancing accessibility and efficiency in medical services[47] - The company has developed a multi-channel marketing strategy, combining online and offline efforts to provide comprehensive health education and medication management services[52] - The company has implemented a digitalized production process, improving efficiency and reducing costs, while establishing a smart manufacturing system centered on modern traditional Chinese medicine[71] Regulatory Environment and Government Support - The government continues to support the development of traditional Chinese medicine, with new policies aimed at promoting innovation and standardization in the industry[103] - The 2024 government work report emphasizes the creation of new growth engines in biomanufacturing and life sciences, indicating a strong focus on the biopharmaceutical sector[104] - The implementation of the "full-chain support for innovative drug development" plan by the State Council highlights the government's commitment to strengthening policy support for the pharmaceutical industry[105] - The ongoing reforms in drug pricing and reimbursement mechanisms are expected to improve the profitability of high-quality innovative drugs[104] Corporate Governance and Management - The company has established a management system for insider information and has implemented a registration system for insiders to ensure fair and transparent information disclosure[170] - The board of directors includes independent directors constituting more than one-third of its members, ensuring governance and oversight[170] - The company has actively revised its governance documents, including the Independent Director System and the Related Party Transaction Management System, to enhance operational transparency[173] - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to CNY 2,376.70 million[178] - The company has established a performance-based remuneration system for senior management, linking it to annual operational performance[183] Employee Engagement and Development - The company emphasizes a comprehensive compensation system to enhance employee engagement and align salaries with performance and skills[196] - Continuous internal training programs are implemented to improve employee skills and knowledge in emerging technologies[198] - The company aims to build a highly professional and innovative team to support its sustainable development[198] - The company has a total of 919,080 shares held by the resigned board members, with no changes reported during the year[178] Subsidiaries and Investments - The company’s subsidiaries are involved in various sectors, including drug production, sales, and technology services, contributing to a diversified revenue stream[140] - The company has disposed of 36.46% of its holdings in I-MAB, recovering the entire investment cost and generating a profit of 591 million RMB[137] - The company holds a 65.00% stake in Tian Shi Li International Gene Network Drug Innovation Center, which is not consolidated in the financial statements due to lack of control[135] Future Outlook and Strategic Initiatives - The company is positioned to leverage its existing resources and expertise for future growth opportunities in the pharmaceutical sector[178] - The company is focusing on the development of traditional Chinese medicine, supported by national policies aimed at enhancing the recognition and trust in TCM[143] - The biopharmaceutical sector is expected to experience significant growth, driven by government policies encouraging innovation and strategic development in the industry[143] - The company is adapting to the shift in disease patterns in China, with a focus on chronic diseases as the primary health concern for residents[142]

本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 经天健会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，天 士力医药集团股份有限公司（以下简称"公司"、"上市公司"）期末可供分配利 润为人民币 6,920,089,279.23 元。公司 2024 年年度拟以实施权益分派股权登记日 登记的总股本为基数分配利润。本次利润分配预案如下： 证券代码：600535 证券简称：天士力 编号：临 2025-005 号 天士力医药集团股份有限公司 2024 年度利润分配预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 每股分配比例：每10股分派现金股利2元（含税）。 上市公司拟向全体股东每 10 股派发现金红利 2 元（含税）。截至 2024 年 12 月 31 日，公司总股本 1,493,950,005 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 6.02%, ranking 6th among 31 primary industries, outperforming the CSI 300 index which rose by 3.19% [3][10] - The PE (TTM overall method, excluding negative values) for the pharmaceutical and biotechnology industry as of February 14, 2025, is 26.68x, up from 25.41x in the previous period, indicating an upward valuation trend [12] - The AI medical market in China is projected to grow significantly, with a compound annual growth rate (CAGR) of 43.1%, increasing from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033 [5] Industry Review - The top-performing sub-industries during the reporting period were hospitals and medical devices, with increases of 14.31% and 12.54% respectively, while blood products and chemical preparations lagged behind with increases of 0.57% and 2.38% [3][10] - A total of 249 out of 501 tracked pharmaceutical and biotechnology companies disclosed their 2024 performance forecasts, with 43 companies expecting significant profit increases of 30% or more [4] Important Industry News - The National Medical Insurance Administration released a list of key tasks for 2025, aiming for 80% of regions to achieve instant settlement with designated medical institutions by the end of the year [15] - The approval of the first domestic biosimilar drug "Westuximab" by Kelun-Botai marks a significant milestone in the industry [22] - Johnson & Johnson received approval for two first-in-class bispecific antibodies, "Reiko" and "Takuiko," expanding its product offerings in the market [28] Investment Recommendations - The rise of AI technology in healthcare is expected to deepen, with over 30 companies accelerating the integration of AI technologies across various applications, including drug development and clinical diagnostics [5] - The acquisition of a 28% stake in Tian Shi Li by China Resources Sanjiu for approximately 6.2 billion yuan is anticipated to enhance market competitiveness and resource integration [38][40]

2025 年 2 月 6 日，天士力医药集团股份有限公司（以下简称"天士力""公 司"）收到华润三九医药股份有限公司（以下简称"华润三九"）发来的通知，华 润三九已于近日收到中国华润有限公司（以下简称"中国华润"）转发的国务院 国有资产监督管理委员会（以下简称"国务院国资委"）《关于华润三九医药股份 有限公司收购天士力医药集团股份有限公司有关事项的批复》（国资产权[2025] 30 号），具体事项如下： 一、基本情况概述 公司于 2024 年 8 月 5 日披露了《天士力关于控股股东及其一致行动人签署< 股份转让协议>暨控制权变更的提示性公告》（公告编号：临 2024-030 号），公司 控股股东天士力生物医药产业集团有限公司（以下简称"天士力集团"）及其一 致行动人天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发展合伙企业 （有限合伙）、天津鸿勋科技发展合伙企业（有限合伙）、天津通明科技发展合伙 企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展 合伙企业（有限合伙）与华润三九签订了《股份转让协议》。根据协议内容，天 士力集团及其一致行动人拟通过协议转让的方式向华润三九合计转让其所 ...